Published in Curr Alzheimer Res on July 01, 2006
100 years and counting: prospects for defeating Alzheimer's disease. Science (2006) 3.24
Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A (2011) 1.67
Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases. Biochim Biophys Acta (2008) 1.01
Sleep disturbances in Alzheimer's and Parkinson's diseases. Neuromolecular Med (2012) 1.00
The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen. J Neural Transm (Vienna) (2011) 0.94
Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim Biophys Acta (2011) 0.91
Novel 5' untranslated region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: implications for down syndrome and Alzheimer's disease. PLoS One (2013) 0.91
Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease. Pharmacol Ther (2013) 0.90
Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease. Mol Neurodegener (2010) 0.86
Neocortex and allocortex respond differentially to cellular stress in vitro and aging in vivo. PLoS One (2013) 0.84
Alzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: maintenance of brain iron homeostasis. Biochem Pharmacol (2014) 0.79
Serotonin 6 receptor controls alzheimer's disease and depression. Oncotarget (2015) 0.78
Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol (2005) 11.63
Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol (2008) 9.24
Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov (2004) 5.82
The spectrum of disease in chronic traumatic encephalopathy. Brain (2012) 5.10
Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell (2010) 5.09
The neurobiology of zinc in health and disease. Nat Rev Neurosci (2005) 5.07
BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med (2008) 4.20
Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci U S A (2005) 3.83
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol (2003) 3.58
Clinical presentation of chronic traumatic encephalopathy. Neurology (2013) 3.53
Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med (2012) 3.31
Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol (2012) 3.03
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol (2008) 3.03
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron (2003) 2.80
The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One (2010) 2.78
Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. Brain (2011) 2.76
TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity. Nature (2006) 2.56
The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr (2009) 2.54
Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell (2010) 2.46
Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol (2008) 2.44
Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron (2008) 2.30
Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med (2006) 2.28
Zinc in the physiology and pathology of the CNS. Nat Rev Neurosci (2009) 2.12
Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell (2010) 2.08
Necrostatin-1 reduces histopathology and improves functional outcome after controlled cortical impact in mice. J Cereb Blood Flow Metab (2008) 2.06
An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem (2002) 2.00
Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care (2013) 1.99
Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem (2002) 1.99
Metals in Alzheimer's and Parkinson's diseases. Curr Opin Chem Biol (2008) 1.98
Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem (2005) 1.95
N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. Biol Psychiatry (2008) 1.93
Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet (2003) 1.91
Necroptosis, a novel form of caspase-independent cell death, contributes to neuronal damage in a retinal ischemia-reperfusion injury model. J Neurosci Res (2010) 1.89
Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol (2003) 1.85
Decreased expression of heat shock protein 72 in skeletal muscle of patients with type 2 diabetes correlates with insulin resistance. Diabetes (2002) 1.78
Cognitive loss in zinc transporter-3 knock-out mice: a phenocopy for the synaptic and memory deficits of Alzheimer's disease? J Neurosci (2010) 1.74
Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem (2002) 1.74
N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biol Psychiatry (2008) 1.73
Structure-activity relationship study of novel necroptosis inhibitors. Bioorg Med Chem Lett (2005) 1.72
Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood (2011) 1.61
Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology (2007) 1.61
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis (2010) 1.57
Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS One (2007) 1.55
In vivo reduction of amyloid-beta by a mutant copper transporter. Proc Natl Acad Sci U S A (2003) 1.52
The CNS glycoprotein Shadoo has PrP(C)-like protective properties and displays reduced levels in prion infections. EMBO J (2007) 1.49
Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian imaging, biomarkers and lifestyle (AIBL) study of ageing. Int Psychogeriatr (2011) 1.49
The neurophysiology and pathology of brain zinc. J Neurosci (2011) 1.46
Insulin-like signaling determines survival during stress via posttranscriptional mechanisms in C. elegans. Cell Metab (2010) 1.46
The expanding universe of prion diseases. PLoS Pathog (2006) 1.45
Decreased serum zinc is an effect of ageing and not Alzheimer's disease. Metallomics (2014) 1.44
N-acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr (2011) 1.43
Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/IkappaB kinase alpha pathway targeting activator protein-1. J Biol Chem (2008) 1.41
Interactome analyses identify ties of PrP and its mammalian paralogs to oligomannosidic N-glycans and endoplasmic reticulum-derived chaperones. PLoS Pathog (2009) 1.41
Copper in the brain and Alzheimer's disease. J Biol Inorg Chem (2009) 1.40
Mapping Cu(II) binding sites in prion proteins by diethyl pyrocarbonate modification and matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometric footprinting. J Biol Chem (2001) 1.39
DHA supplemented in peptamen diet offers no advantage in pathways to amyloidosis: is it time to evaluate composite lipid diet? PLoS One (2011) 1.39
Metals and Alzheimer's disease. J Alzheimers Dis (2006) 1.39
The in vivo brain interactome of the amyloid precursor protein. Mol Cell Proteomics (2007) 1.38
Structure-activity relationship study of novel tissue transglutaminase inhibitors. Bioorg Med Chem Lett (2005) 1.38
Mechanisms of A beta mediated neurodegeneration in Alzheimer's disease. Int J Biochem Cell Biol (2007) 1.36
A new class of small molecule inhibitor of BMP signaling. PLoS One (2013) 1.36
The structural basis of Cryptosporidium -specific IMP dehydrogenase inhibitor selectivity. J Am Chem Soc (2010) 1.35
Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. PLoS One (2010) 1.35
MicroRNAs can regulate human APP levels. Mol Neurodegener (2008) 1.34
Skeletal muscle cells and adipocytes differ in their reliance on TC10 and Rac for insulin-induced actin remodeling. Mol Endocrinol (2003) 1.33
Triazole inhibitors of Cryptosporidium parvum inosine 5'-monophosphate dehydrogenase. J Med Chem (2009) 1.33
The Caenorhabditis elegans A beta 1-42 model of Alzheimer disease predominantly expresses A beta 3-42. J Biol Chem (2009) 1.32
The role of metallobiology and amyloid-β peptides in Alzheimer's disease. J Neurochem (2011) 1.31
Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry (2004) 1.30
Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease. J Psychiatry Neurosci (2004) 1.30
Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem (2006) 1.29
Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation. Proc Natl Acad Sci U S A (2009) 1.29
Metal dyshomeostasis and oxidative stress in Alzheimer's disease. Neurochem Int (2012) 1.29
Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics. Prog Neurobiol (2010) 1.29
Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J (2004) 1.29
The prion protein family: diversity, rivalry, and dysfunction. Biochim Biophys Acta (2007) 1.28
Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Ann N Y Acad Sci (2004) 1.28
Structure-activity relationship study of tricyclic necroptosis inhibitors. J Med Chem (2007) 1.27
Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function. Anesthesiology (2010) 1.27
Biological metals and metal-targeting compounds in major neurodegenerative diseases. Chem Soc Rev (2014) 1.27
Metal ions, pH, and cholesterol regulate the interactions of Alzheimer's disease amyloid-beta peptide with membrane lipid. J Biol Chem (2002) 1.26
A review of independent component analysis application to microarray gene expression data. Biotechniques (2008) 1.24
Copper transport into the secretory pathway is regulated by oxygen in macrophages. J Cell Sci (2009) 1.24
Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A beta in plasma. Neurobiol Dis (2006) 1.23
Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome. PLoS One (2010) 1.23
Genetic mapping of activity determinants within cellular prion proteins: N-terminal modules in PrPC offset pro-apoptotic activity of the Doppel helix B/B' region. J Biol Chem (2004) 1.23
11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. Nucl Med Biol (2003) 1.22
Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides. J Biol Inorg Chem (2004) 1.21
Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci (2008) 1.21
N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease. Curr Alzheimer Res (2012) 1.20
Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1. J Biol Chem (2010) 1.20